MedTrace Logo

The Effects of Postbiotic Supplementation in Female Athletes

NCT07580118 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-05-12

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if a postbiotic supplement can reduce stomach and gut symptoms in physically active women.

The main questions it aims to answer are:

Does the supplement reduce gut symptoms during the menstrual cycle? Does it improve symptoms related to exercise?

Researchers will compare the postbiotic supplement to a placebo (a look-alike capsule that contains no active ingredient) to see if the supplement works.

Participants will be physically active, premenopausal female athletes.

Participants will:

Take either the postbiotic supplement or a placebo each day for two menstrual cycles Track their menstrual cycle and training Report gut symptoms using regular questionnaires Provide stool samples to assess gut health

This study will help researchers understand whether postbiotic supplements can improve gut health and reduce symptoms that may affect training and performance in female athletes.

Conditions

  • Gastrointestinal Symptoms
  • Menstrual Cycle

Interventions

DIETARY_SUPPLEMENT

Postbiotic

Postbiotic supplement (Humiome® Post LB) administered as two oral capsules daily, providing 340 mg of postbiotic per day. The supplement contains heat-inactivated microbial strains and fermentation products. Participants will take the supplement daily for two consecutive menstrual cycles following a one-cycle placebo run-in phase.

DIETARY_SUPPLEMENT

Placebo

Placebo capsules containing microcrystalline cellulose, matched in appearance to the postbiotic supplement. Participants will take two capsules daily during a one-cycle placebo run-in phase and, if randomized to the placebo group, continue for two additional menstrual cycles.

Sponsors & Collaborators

  • Liverpool John Moores University

    lead OTHER

Principal Investigators

  • Kelsie Johnson, PhD · Liverpool John Moores University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-05-05
Primary Completion
2027-03-30
Completion
2027-05-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07580118 on ClinicalTrials.gov